Vertex Pharmaceuticals Inc. - Liver Disease Information

NEW YORK (Reuters) - A closely watched experimental hepatitis C treatment being developed by Vertex Pharmaceuticals Inc led to a 75 percent cure rate in a pivotal late-stage trial of previously untreated patients, the company said on Tuesday.The results from the first ...

VX-222 was well-tolerated across all four dose groups through three days of dosing, with all adverse events being mild to moderate in severity-. VRTX) today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus (HCV) polymerase ...

Correction: Vertex Hepatitis C DrugIn a story Jan. 11 about Vertex Pharmaceuticals Inc. and its hepatitis C drug, The Associated Press misstated when the company will seek regulatory approval for the drug. Approval will be requested in the second half of 2010, ...

Correction: Vertex Hepatis C DrugIn a story Jan. 11 about Vertex Pharmaceuticals Inc. and its hepatitis C drug, The Associated Press misstated when the company will seek regulatory approval for the drug. Approval will be requested in the second half of 2010, ...

Topic: Vertex Pharmaceuticals Inc.

Vertex hep C drug achieves 75 pct cure rate: study

Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Days in Phase 1b Trial

Correction: Vertex Hepatitis C Drug

Correction: Vertex Hepatis C Drug

From Around the Web

Video Gallery

Follow this Topic with...